Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.
暂无分享,去创建一个
[1] A. Rosenwald,et al. 2‐D PAGE‐based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma , 2009, Electrophoresis.
[2] J. Leonard,et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] K. Manova,et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. , 2008, Blood.
[4] D. McConkey,et al. Mechanisms of proteasome inhibitor action and resistance in cancer. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[5] M. Wang,et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo , 2008, Leukemia.
[6] Sang Gyun Kim,et al. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. , 2008, Cancer research.
[7] J. Raemaekers,et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] P. Kloetzel,et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma , 2007, European journal of haematology.
[9] W. Hiddemann,et al. Proteome‐ and microarray‐based expression analysis of lymphoma cell lines identifies a p53‐centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma , 2007, Electrophoresis.
[10] E. Campo,et al. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. , 2007, Blood.
[11] W. Hiddemann,et al. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma , 2007, Leukemia.
[12] A. Rosenwald,et al. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.